GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biotricity Inc (NAS:BTCY) » Definitions » Sloan Ratio %

Biotricity (Biotricity) Sloan Ratio % : 0.00% (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Biotricity Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Biotricity's Sloan Ratio for the quarter that ended in Dec. 2023 was 0.00%.

As of Dec. 2023, Biotricity has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


Biotricity Sloan Ratio % Historical Data

The historical data trend for Biotricity's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotricity Sloan Ratio % Chart

Biotricity Annual Data
Trend Aug14 Aug15 Dec16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Sloan Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -83.57 -

Biotricity Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Biotricity's Sloan Ratio %

For the Medical Devices subindustry, Biotricity's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biotricity's Sloan Ratio % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Biotricity's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Biotricity's Sloan Ratio % falls into.



Biotricity Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Biotricity's Sloan Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Sloan Ratio=(Net Income (A: Mar. 2023 )-Cash Flow from Operations (A: Mar. 2023 )
-Cash Flow from Investing (A: Mar. 2023 ))/Total Assets (A: Mar. 2023 )
=(-18.658--13.548
-0)/6.511
=-78.48%

Biotricity's Sloan Ratio for the quarter that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Dec. 2023 )
=(-14.584--7.406
-0)/5.486
=-130.84%

Biotricity's Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was -4.672 (Mar. 2023 ) + -3.413 (Jun. 2023 ) + -3.691 (Sep. 2023 ) + -2.808 (Dec. 2023 ) = $-14.58 Mil.
Biotricity's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 was -1.878 (Mar. 2023 ) + -1.832 (Jun. 2023 ) + -2.39 (Sep. 2023 ) + -1.306 (Dec. 2023 ) = $-7.41 Mil.
Biotricity's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 was 0 (Mar. 2023 ) + 0 (Jun. 2023 ) + 0 (Sep. 2023 ) + 0 (Dec. 2023 ) = $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biotricity  (NAS:BTCY) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Dec. 2023, Biotricity has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


Biotricity Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Biotricity's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Biotricity (Biotricity) Business Description

Traded in Other Exchanges
Address
275 Shoreline Drive, Suite 150, Redwood City, CA, USA, 94065
Biotricity Inc is a medical technology company that focuses on biometric data monitoring solutions. It aims to deliver remote monitoring solutions to the healthcare & consumer markets, with a focus on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. Biotricity is expanding medical-grade monitoring into the consumer market via its Biolife solution, which empowers users to self-manage chronic conditions. Its products include Bioflux, which is a mobile cardiac telemetry (MCT) device that provides real-time monitoring and transmission of ambulatory patients' ECG information; Biocare Telemed, which is a virtual clinic platform that enables clinicians to provide outstanding patient care remotely; Bioheart, which is a personal heart monitor; and Biocare health.
Executives
Chester P White director 447 BATTERY STREET, SUITE 230, SAN FRANCISCO CA 94111
Ronald W. Mcclurg director C/O NEUROONE MEDICAL TECHNOLOGIES CORP, 7599 ANAGRAM DR, EDEN PRAIRIE MN 55344
David A Rosa director 10901 RED CIRCLE DRIVE, SUITE 150, MINNETONKA MN 55343
Stephen Salmon director 1177 HAGEN ROAD, NAPA CA 94558
Patricia J Kennedy director 275 SHORELINE DRIVE, SUITE 150, REDWOOD CITY CA 94065
Norman M. Betts director 275 SHORELINE DRIVE, SUITE 150, REDWOOD CITY CA 94065
Waqaas Al-siddiq director, 10 percent owner, officer: CEO and Chairman of the Board C/O 275 SHORELINE DRIVE, SUITE 150, REDWOOD CITY CA 94065
John Ayanoglou officer: Chief Financial Officer C/O 275 SHORELINE DRIVE, SUITE 150, REDWOOD CITY CA 94065